WHO. Global Tuberculosis Report 2023. World Health Organization https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 (2023).

The Economist Intelligence Unit. It’s time to end drug-resistant tuberculosis. The Economist https://www.eiu.com/graphics/marketing/pdf/its-time-to-end-drug-resistant-tuberculosis-full-report.pdf (2019).

Paulson, T. Epidemiology: a mortal foe. Nature 502, S2–S3 (2013).

Article  PubMed  Google Scholar 

WHO. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update. World Health Organization https://www.who.int/publications/i/item/9789240063129 (2022).

WHO. Meeting Report of the WHO Expert Consultation on Drug-Resistant Tuberculosis Treatment Outcome Definitions. World Health Organization https://www.who.int/publications/i/item/9789240022195 (2021).

WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment (WHO, 2019).

WHO. Global Tuberculosis Report 2022. World Health Organization https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (2022).

O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. AMR https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (2016).

Gunther, G. et al. Treatment outcomes in multidrug-resistant tuberculosis. N. Engl. J. Med. 375, 1103–1105 (2016).

Article  PubMed  Google Scholar 

Gunther, G. et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin. Microbiol. Infect. 29, 77–84 (2023).

Article  PubMed  Google Scholar 

WHO. Ten Threats to Global Health in 2019. World Health Organization https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (2019).

WHO. Global Research Agenda for Antimicrobial Resistance in Human Health. World Health Organization https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health#:~:Text=It%20aims%20to%20guide%20policy,and%2Dmiddle%2Dincome%20countries (2023).

Dheda, K. et al. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 198, 1208–1219 (2018). Comprehensive study outlining the differential penetration of drugs into TB cavities and its association with resistance amplification.

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO. WHO TB country, regional and global profiles. World Health Organization https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&entity_type=%22country%22&iso2=%22AF%22 (2022).

Dheda, K. et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir. Med. 10, 603–622 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bykov, I. et al. Factors contributing to the high prevalence of multidrug-resistance/rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk Krai region of Russia. BMC Infect. Dis. 22, 612 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Faustini, A., Hall, A. J. & Perucci, C. A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61, 158–163 (2006).

Article  CAS  PubMed  Google Scholar 

Jeong, H. E. et al. Socioeconomic disparities and multidrug-resistant tuberculosis in South Korea: focus on immigrants and income levels. J. Microbiol. Immunol. Infect. 56, 424–428 (2023).

Article  PubMed  Google Scholar 

Feng, M. et al. Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis. Public Health Nurs. 36, 257–269 (2019).

Article  PubMed  Google Scholar 

Wingfield, T., Tovar, M. A., Datta, S., Saunders, M. J. & Evans, C. A. Addressing social determinants to end tuberculosis. Lancet 391, 1129–1132 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Janssens, J. P. & Rieder, H. L. An ecological analysis of incidence of tuberculosis and ‘per capita′ gross domestic product. Eur. Respir. J. 32, 1415 (2008).

Article  PubMed  Google Scholar 

Lienhardt, C. et al. Global tuberculosis control: lessons learnt and future prospects. Nat. Rev. Microbiol. 10, 407–416 (2012).

Article  CAS  PubMed  Google Scholar 

Oxlade, O. & Murray, M. Tuberculosis and poverty: why are the poor at greater risk in India? PLoS ONE 7, e47533 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhargava, A., Bhargava, M., Beneditti, A. & Kurpad, A. Attributable is preventable: corrected and revised estimates of population attributable fraction of TB related to undernutrition in 30 high TB burden countries. J. Clin. Tuberc. Other Mycobact. Dis. 27, 100309 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sultana, Z. Z. et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 21, 51 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Bastard, M. et al. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: multicenter cohort study. PLoS ONE 13, e0193491 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).

Article  Google Scholar 

Tegegne, B. S., Mengesha, M. M., Teferra, A. A., Awoke, M. A. & Habtewold, T. D. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst. Rev. 7, 161 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Xu, G., Hu, X., Lian, Y. & Li, X. Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 23, 813 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Du, D. H. et al. The effect of M. tuberculosis lineage on clinical phenotype. Preprint at medRxiv https://doi.org/10.1101/2023.03.14.23287284 (2023).

Marx, F. M. et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin. Infect. Dis. 58, 1676–1683 (2014).

Article  CAS  PubMed  Google Scholar 

Becerra, M. C. et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ 367, l5894 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Theron, G. et al. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat. Med. 26, 1435–1443 (2020). Work indicating that DR-TB strains were as infectious as DS-TB strains, and that infectiousness was not associated with M. tuberculosis genetic variants (suggesting that epigenetic factors or host–pathogen interactions are likely important in the pathogenesis of resistance amplification).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah, N. S. et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N. Engl. J. Med. 376, 243–253 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Loiseau, C. et al. The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot. Nat. Commun. 14, 1988 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bateson, A. et al. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J. Antimicrob. Chemother. 77, 1685–1693 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gómez-González, P. J. et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci. Rep. 11, 19431 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Brown, T. S. et al. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova. Microb. Genom. 7, 000620 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Dheda, K. et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir. Med. 7, 820–826 (2019).

Article  CAS  PubMed  Google Scholar 

Adam, D. C. et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat. Med. 26, 1714–1719 (2020).

Article  CAS  PubMed  Google Scholar 

Perdigão, J. et al. Using genomics to understand the origin and dispersion of multidrug and extensively drug resistant tuberculosis in Portugal. Sci. Rep. 10, 2600 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Salvato, R. S. et al. Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil. Int. J. Antimicrob. Agents 58, 106401 (2021).

Article  CAS  PubMed  Google Scholar 

Sara, C. A. et al. Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. ERJ 52, 1800246 (2018).

Article  Google Scholar 

Srilohasin, P. et al. Genomic evidence supporting the clonal expansion of extensively drug-resistant tuberculosis bacteria belonging to a rare proto-Beijing genotype. Emerg. Microbes Infect. 9, 2632–2641 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar